Literature DB >> 6440885

Intraprostatic concentration of ciprofloxacin and its activity against urinary pathogens.

J A Hoogkamp-Korstanje, H J van Oort, J J Schipper, T van der Wal.   

Abstract

The in-vitro activity of ciprofloxacin against 376 urinary pathogens was determined. The minimal inhibitory concentrations for 90% of the Enterobacteriaceae were 0.03-0.23 mg/l, for Pseudomonas aeruginosa 0.37 mg/l, for Streptococcus faecalis 0.75 mg/l and for Staphylococcus aureus 0.92 mg/l. A 100 mg dose of ciprofloxacin was administered intravenously to 25 patients undergoing prostatectomy. The concentrations in prostate and serum were measured at different intervals. Peak levels in prostate were 3.0 micrograms/g attained 20 min after administration. Peak serum levels were 1.2 mg/l attained 20 min after administration. Serum and prostate elimination was slowly. The overall serum: prostate ratio 1:2.1.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6440885     DOI: 10.1093/jac/14.6.641

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Prostatic abscess caused by Streptococcus mutans.

Authors:  C Nguyen; A Dascal; J Mendelson
Journal:  Can J Infect Dis       Date:  1990

2.  The possible role of quinolones in yersiniosis.

Authors:  J A Hoogkamp-Korstanje
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 3.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

4.  Quantitative determination of ofloxacin, ciprofloxacin, norfloxacin and pefloxacin in serum by high pressure liquid chromatography.

Authors:  A J Groeneveld; J R Brouwers
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

5.  Single and multiple dose pharmacokinetics of ciprofloxacin.

Authors:  U Ullmann; W Giebel; A Dalhoff; P Koeppe
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

6.  Fleroxacin (Ro 23-6240) distribution in canine prostatic tissue and fluids.

Authors:  T C Gasser; P H Graversen; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

7.  Treatment of chronic bacterial prostatitis with ciprofloxacin.

Authors:  T N Langemeyer; W H Ferwerda; J A Hoogkamp-Korstanje; E J de Leur; H van Oort; J J Schipper; T van der Wal
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

8.  Ciprofloxacin concentrations in tonsils following single or multiple administrations.

Authors:  N Falser; A Dalhoff; H Weuta
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 9.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 10.  Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1986-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.